Aggressive resection of metastatic disease in selected patients with malignant gastrinoma
- PMID: 2938550
- PMCID: PMC1251117
- DOI: 10.1097/00000658-198604000-00003
Aggressive resection of metastatic disease in selected patients with malignant gastrinoma
Abstract
Fifteen patients with Zollinger-Ellison syndrome followed at the National Institutes of Health with extensive metastatic disease had an actuarial 5-year survival of 20%. Therefore, in 1982 a prospective study to examine the effect and feasibility of removing all gross tumor in selected patients with extensive metastatic disease was instituted. Five patients with extensive metastatic gastrinoma confined to the abdomen in whom imaging studies suggested the possibility of complete surgical resection were entered into this study and underwent attempted complete surgical resection and chemotherapy with streptozotocin, doxorubicin, and 5-fluorouracil. Median follow-up was 24 months. Surgical resection of all gastrinoma was possible in 4/5 patients attempted. In one patient in whom all gross disease could not be resected, the residual tumor progressed and the patient died 19 months after operation. All four patients with all disease resected appeared to benefit since all of them had a significant reduction in antisecretory medications and are enjoying normal activity and work. Three patients have had no detectable tumor on follow-up, and two of these patients are clinically and biochemically "cured" with normal fasting gastrin levels and negative provocative gastrin tests at 14 and 32 months. Therefore, aggressive resection of metastatic disease in selected patients with malignant gastrinoma is recommended.
Similar articles
-
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.Gastroenterology. 1992 Mar;102(3):767-78. doi: 10.1016/0016-5085(92)90157-t. Gastroenterology. 1992. PMID: 1537514 Clinical Trial.
-
A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection.Surgery. 1988 Dec;104(6):1054-63. Surgery. 1988. PMID: 2904182
-
Intra-arterial use of streptozotocin in a case of metastatic malignant gastrinoma.Can Med Assoc J. 1981 Dec 15;125(12):1339-41. Can Med Assoc J. 1981. PMID: 6459842 Free PMC article. No abstract available.
-
Successful treatment of a malignant gastrinoma with streptozotocin.Gut. 1976 Apr;17(4):285-8. doi: 10.1136/gut.17.4.285. Gut. 1976. PMID: 178577 Free PMC article. Review.
-
[Zollinger-Ellison syndrome].Wien Klin Wochenschr. 1984 Feb 17;96(4):138-44. Wien Klin Wochenschr. 1984. PMID: 6324497 Review. German.
Cited by
-
Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.Medicine (Baltimore). 2006 Nov;85(6):295-330. doi: 10.1097/01.md.0000236956.74128.76. Medicine (Baltimore). 2006. PMID: 17108778 Free PMC article.
-
Surgery increases survival in patients with gastrinoma.Ann Surg. 2006 Sep;244(3):410-9. doi: 10.1097/01.sla.0000234802.44320.a5. Ann Surg. 2006. PMID: 16926567 Free PMC article.
-
Localization and resection of gastrinomas in Zollinger-Ellison syndrome.Ann Surg. 1987 May;205(5):550-6. doi: 10.1097/00000658-198705000-00014. Ann Surg. 1987. PMID: 3579402 Free PMC article.
-
Surgical management of malignant islet cell tumors.World J Surg. 1993 Jul-Aug;17(4):498-503. doi: 10.1007/BF01655109. World J Surg. 1993. PMID: 8395750
-
Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome.World J Surg. 1991 Jan-Feb;15(1):151-9. doi: 10.1007/BF01658992. World J Surg. 1991. PMID: 1671617 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical